Orris

Treatment of diphtheria

Reading File
Finding Sources
Searching PubMed

"diphtheria"[MeSH Terms] AND treatment

Searching the Web

diphtheria treatment guidelines antitoxin antibiotics 2024

Reading File
Reading File
Reading File
Reading File
Reading File
Reading Web Page

diphtheria treatment antitoxin antibiotics dosage

Reading File
Reading File
Reading File
Reading File
I now have comprehensive content from multiple authoritative sources. Here is the full treatment overview:

Treatment of Diphtheria

Diphtheria is an acute toxin-mediated disease caused by toxigenic strains of Corynebacterium diphtheriae (and occasionally C. ulcerans). Treatment has three simultaneous pillars: antitoxin, antibiotics, and supportive/airway care. Treatment must begin on clinical suspicion - do NOT wait for microbiological confirmation.

1. Airway Management (First Priority)

Airway obstruction from membrane extension into the larynx and trachea is a life-threatening emergency.
  • Maintain close observation of all patients with laryngeal involvement
  • Early endotracheal intubation should be considered for patients with laryngeal or tracheobronchial disease and worsening stridor
  • If intubation is not possible, surgical tracheostomy may be required
  • Administer supplemental oxygen and humidification
  • Systemic corticosteroids may reduce airway edema and lessen the need for airway intervention (Scott-Brown's ENT)
  • Patients should be placed in respiratory isolation (droplet precautions for pharyngeal diphtheria, contact precautions for cutaneous diphtheria)

2. Diphtheria Antitoxin (DAT) - The Cornerstone

DAT neutralizes circulating, unbound exotoxin. It cannot reverse toxin already bound to tissues - hence the urgency.
"Delaying the administration of the antitoxin is associated with increased mortality... the decision to administer antitoxin should be made based on clinical suspicion and should not await microbiological confirmation." - Scott-Brown's Otorhinolaryngology
Dose based on disease severity and duration:
Clinical PresentationDAT Dose
Pharyngeal/laryngeal involvement, ≤2 days20,000 - 40,000 units IV
Nasopharyngeal lesions40,000 - 60,000 units IV
Systemic disease or disease ≥3 days, OR diffuse neck swelling ("bull neck")80,000 - 100,000 units IV
Cutaneous diphtheriaUsually not required; 20,000-40,000 units may be considered
Important DAT notes:
  • Administer IV (preferred for speed of neutralization)
  • DAT is equine-derived immunoglobulin - perform a conjunctival or intradermal skin sensitivity test before administration. If the patient is sensitive, desensitization is required
  • In the 2024 WHO guidelines, routine skin sensitivity testing before DAT is no longer recommended as a prerequisite - DAT should be given promptly
  • In the US, DAT is not FDA-licensed; contact the CDC at 770-488-7100 to obtain it as an investigational new drug

3. Antibiotics

Antibiotics stop further toxin production by eradicating the organism. They are not a substitute for antitoxin and do not reverse toxin already produced or bound.
First-line:
  • Erythromycin 40 mg/kg/day IV or orally in divided doses (max 2 g/day) for 14 days - preferred; treatment failures more common with penicillin
  • Note (2024 WHO guideline update): WHO now recommends macrolide antibiotics (azithromycin or erythromycin) over penicillin based on evidence review
Alternative:
  • Procaine penicillin G IM: 300,000 units/day every 12h for patients ≤10 kg; 600,000 units/day every 12h for patients >10 kg
  • Azithromycin and clarithromycin have demonstrated activity but are not FDA-approved for this specific indication (US)
Key point from Goodman & Gilman's: "Antibiotics do not alter the course of an acute infection with diphtheria or decrease the risk of complications. Antitoxin is indicated in the treatment of acute infection."
Post-antibiotic culture:
  • After completing therapy, obtain two consecutive negative cultures 24 hours apart to confirm bacterial clearance
  • If cultures remain positive after initial course, extend erythromycin for an additional 10 days

4. Cardiac Monitoring and Management of Myocarditis

Myocarditis is the most dangerous systemic complication, appearing 1-2 weeks after onset (earlier in severe cases).
  • Serial ECGs are mandatory - ECG changes occur in up to two-thirds of patients (ST-T changes, varying degrees of AV block, dysrhythmias)
  • Left bundle branch block or complete AV block carries a 60-90% mortality rate
  • Serum troponin correlates with myocarditis severity; echocardiogram may show dilated/hypertrophic cardiomyopathy
  • Treatment is supportive - no data support steroid use for diphtheritic myocarditis
  • Cardiology consult for any patient with ECG changes

5. Management of Neurological Complications

Neuropathy follows a biphasic pattern (Adams & Victor's Neurology):
  1. Early (days 5-12): Palatal paralysis (nasal voice, regurgitation, dysphagia), then other cranial nerve involvement
  2. Week 2-3: Ciliary body paralysis - loss of accommodation, blurred vision (preserved pupillary light reflex - distinguishes from Argyll Robertson pupil)
  3. Weeks 5-8: Delayed sensorimotor polyneuropathy - can resemble Guillain-Barré syndrome (elevated CSF protein, acellular)
"There is no specific treatment for the neurologic complications of diphtheria." Early antitoxin (within 48 hours of infection) lessens the incidence and severity of neuropathy. Supportive care, respiratory support for diaphragmatic paralysis, and rehabilitation are the mainstays.

6. Management of Carrier State

  • Oral penicillin G or erythromycin for 7 days, OR
  • IM benzathine penicillin: 600,000 units for those <30 kg; 1,200,000 units for those >30 kg
  • Active immunization for unimmunized/partially immunized carriers
  • Repeat cultures at 2 weeks; if positive, give erythromycin for 10 more days

7. Management of Close Contacts

  • Obtain cultures from all close contacts; surveillance for 7 days
  • Prophylactic antibiotics: same regimen as for carriers
  • Immunization booster: previously immunized contacts whose last dose was >5 years ago should receive a diphtheria toxoid booster (DTaP/DT/Td as age-appropriate)
  • Unimmunized contacts: initiate active immunization series
  • DAT is not recommended for contacts due to risk of horse serum allergy

8. Cutaneous Diphtheria

  • Debridement of necrotic tissue and vigorous wound cleansing
  • A course of antibiotics (erythromycin or penicillin, 7-10 days)
  • DAT not typically required (CDC); 20,000-40,000 units may be considered but evidence is limited

9. Disposition

All patients with possible pharyngeal diphtheria should be:
  • Isolated (droplet precautions)
  • Admitted to hospital for monitoring
  • Monitored with serial ECGs for arrhythmias/conduction block
  • Cardiology consulted if myocarditis suspected
  • CDC notified for all suspected or confirmed cases

Summary Table

ComponentTreatment
Antitoxin (DAT)20,000-100,000 units IV based on severity; give before culture results
Antibiotics (first-line)Erythromycin 40 mg/kg/day (max 2 g) for 14 days
Antibiotics (alternative)Procaine penicillin G IM
WHO 2024 preferenceMacrolides (azithromycin/erythromycin) over penicillin
AirwayEarly intubation/tracheostomy if laryngeal involvement
CardiacSerial ECGs, supportive care, cardiology consult
NeurologicalSupportive care; no specific therapy
Carrier eradicationPenicillin G or erythromycin x 7 days, OR benzathine PCN IM
IsolationDroplet (respiratory); Contact (cutaneous)
Sources:
2024 Update: The WHO's first-ever clinical management guideline (February 2024) updated two key points: (1) macrolide antibiotics are now preferred over penicillin, and (2) routine skin sensitivity testing before DAT administration is no longer recommended as a prerequisite - prompt DAT administration takes priority.
This is a shared conversation. Sign in to Orris to start your own chat.